The cheapest line in your model is the one nobody owns

Tax and customs exposure is the sixth dimension of market entry and the one almost no assessment measures. Here is what sits in it, and why the numbers moved this year.

Ask a market entry team what a medicine costs to land in a market and you will get a transfer price, a distributor margin and a reimbursed price. Ask who owns the duty rate, the VAT recovery position and the customs value, and the answers get vague. Those three usually sit with tax, logistics and business development respectively, and no one function models them together.

For thirty years that was survivable, because for the largest markets the tariff answer was zero. That is no longer reliably true.

The zero-for-zero baseline, and how thin it is

Most people who know anything about pharmaceutical tariffs know that medicines trade duty free. The instrument behind that belief is a plurilateral arrangement from the Uruguay Round, recorded in GATT document L/7430 and known as the Pharma Agreement.¹

It is worth knowing exactly what it covers, because it is narrower than its reputation.

It has eight participants. Canada, the European Union, Japan, Macao (China), Norway, Switzerland, the United Kingdom and the United States.¹ That is the whole list. China, India, Brazil, Russia, South Korea, Mexico, Turkey, Indonesia, Vietnam, Saudi Arabia and the rest of the Gulf, Nigeria, Egypt and Argentina are not participants.

It covers a great deal within those eight. Finished products in HS Chapter 30, plus headings 2936, 2937, 2939 and 2941, plus active ingredients and chemical compounds listed across four annexes: over 7,000 substances in total. Annex I covers actives bearing an International Non-proprietary Name, Annex II designated prefixes and suffixes for salts, esters and hydrates, Annex III further salts and esters classified elsewhere, Annex IV products used in manufacture.^{1 2}

Because participants apply it on a most-favoured-nation basis, every WTO member benefits from it whether or not they reciprocate. Exports from India or China enter the eight duty free. Exports into India or China do not get the same treatment in return. The arrangement is one-directional by design.

And the product list has not been updated since 2010. The 1994 record of discussions provided for participants to meet under the Council for Trade in Goods "normally at least once every three years" to review coverage and add products by consensus.² There have been four updates: 1996, 1998, 2007 and 2010.¹ On a three-year cycle, the fifth is sixteen years overdue.

Sit with that. A molecule approved in 2011 is not on a list that was last agreed in 2010, and additions require consensus among all participants. The duty-free status of the modern pharmacopoeia rests substantially on the fact that applied rates in those markets happen to be zero anyway, not on a binding that names the product.

Then one participant charged 100 percent

On 2 April 2026 the United States, a Pharma Agreement participant with zero bound rates across Chapter 30, imposed tariffs of up to 100 percent ad valorem on imported patented pharmaceuticals and their active ingredients, under the national security authority at Section 232 of the Trade Expansion Act.³

The rate structure has five levels: 100 percent as the base, 20 percent with an approved onshoring plan, 15 percent for Japan, the EU, South Korea and Switzerland with Liechtenstein, 10 percent for the United Kingdom since reduced to zero, and zero until January 2029 for companies holding a most-favored-nation pricing agreement with the US health department.^{3 4} Generics, biosimilars, orphan drugs whose indications are all orphan-designated, cell and gene therapies, antibody drug conjugates, plasma-derived therapies and several other categories are outside it.

The first tranche took effect on 31 July 2026 and the rest applies from 29 September.⁵

We make no claim here about whether this is consistent with the arrangement in section one. We could not locate any WTO notification or invocation of the security exception in respect of it, and we did not search dispute records, so we are not going to assert that either exists or does not.

What we will say is narrower and harder to argue with: the assumption that pharmaceutical tariffs are structurally zero, which underpinned three decades of landed cost modelling, has an exception large enough to change portfolio decisions. Orphan designation is now a tariff position. So is biosimilar status. So is whether you signed a pricing agreement.

Where duties always bit, and where we will not guess

Outside the eight participants, tariffs on finished pharmaceuticals are ordinary trade policy and vary considerably.

We can verify two structures cleanly.

China reduced import tariffs to zero on all ordinary drugs including anti-cancer products, alkaloid anti-cancer drugs and imported traditional Chinese medicines, effective 1 May 2018.⁶ That was unilateral, outside the Pharma Agreement, and it is the reason a market people assume is protectionist on medicines is not, on this axis.

The Eurasian Economic Union shows the import-substitution shape in its purest form. Heading 3003, medicaments not put up in doses, is zero-rated across all subheadings. Heading 3004, dosed and retail-packaged, runs 3 to 5 percent, with insulin at zero, corticosteroids at 3 to 4, vitamins at 4 to 5. The protection sits exactly at the packaging boundary.⁷ Bulk in free, finished goods taxed.

India operates through exemption rather than a low headline. The 2025-26 Union Budget added 36 lifesaving medicines to the list fully exempted from basic customs duty, put six more at a concessional 5 percent, applied the same rate to the bulk drugs used to make them, and added 37 medicines supplied under patient assistance programmes.⁸ Note the structure: relief is a list you have to be on.

For Brazil, Argentina, Indonesia, Nigeria, Egypt, Turkey and Vietnam we could not retrieve Chapter 30 applied rates from official schedules. Several national tariff portals were unreachable and one large schedule download was blocked. We are not going to publish rates we could not open, and neither should anything you rely on. The relevant point stands without them: if your market is not one of the eight, somebody has set a rate, and it is a number you should have rather than assume.

The VAT trap is worse than the tariff

Here is the part that catches sophisticated companies.

Zero-rating and exemption sound like the same relief. They are opposites for a supplier. A zero-rated supply is a taxable supply charged at nought, so input tax stays recoverable. An exempt supply is outside the taxable base, so input tax attributable to it is blocked and becomes a real absorbed cost.

The European Commission's own terminology gives the game away: it calls a zero rate "an exemption with right of deduction."⁹ Egypt's VAT law puts the other side in one line, listing exempted goods and services among the categories where "the deduction shall not apply."¹⁰

The cleanest live illustration sits in the United Kingdom, in one market, for one molecule. Qualifying goods dispensed to an individual on prescription by a registered pharmacist are zero-rated under Schedule 8 of the VAT Act 1994.¹¹ But where the same drug is administered to the same patient in the course of treatment, the charge is exempt, and HMRC states the consequence plainly: "you cannot normally deduct input tax that relates to your exempt supplies. This includes VAT incurred on the drugs or appliances that doctors have personally administered."¹²

Identical molecule. Identical patient. Opposite recovery position, determined entirely by the delivery channel. A shift from retail dispensing to clinician-administered delivery, which is a clinical and commercial decision, moves the VAT recovery position, and almost nobody models it that way.

Across the EU the rate spread on pharmaceutical products is wide even before that distinction bites: zero in Ireland and Lithuania for oral products, 2.1 percent in France, 4 percent in Spain and Italy, 7 percent in Germany, 25 percent in Denmark, which applies its standard rate with no relief at all.¹³ Those figures reflect the position at 1 January 2021, before the 2022 reform of the EU rate framework, so treat them as the shape of the thing and check any single country live.

The royalty that raises your duty

The last one is the quietest and the most expensive.

Under the WTO Customs Valuation Agreement, customs value is normally the transaction value, and Article 8 requires certain amounts to be added to it. Article 8(1)(c) covers royalties and licence fees that the buyer must pay as a condition of sale of the imported goods.¹⁴

The World Customs Organization's Advisory Opinion 4.17 works through a case where the addition did not apply: a franchisee paying royalties on gross sales of finished products, where the imported inputs were unpatented and unbranded. The conclusion was that those royalties "are not to be added to the price actually paid or payable for the imported goods under the provisions of Article 8.1(c)", because they related to brands and business systems rather than to the imported goods.¹⁵

Now invert those facts into the normal shape of a pharmaceutical in-licensing deal. The imported article is the patented product or the patented active ingredient. The royalty is payable as a condition of being supplied it. On those facts the addition is engaged.

And the cost compounds. The royalty goes into the customs value. Duty is charged on the larger base. Import VAT is then charged on the duty-inclusive value. A term agreed in a licensing negotiation raises landed cost twice, through a mechanism that sits in no one's model, in a line item that business development does not own and tax does not see until the goods move.

Free zones defer, they do not forgive

Free zones are frequently sold as a duty solution. They are a timing solution.

The Revised Kyoto Convention defines a free zone as part of a territory where goods introduced are "generally regarded, insofar as import duties and taxes are concerned, as being outside the Customs territory", and requires national law to specify when value, quantity and applicable rates are determined on removal.¹⁶

The Gulf Cooperation Council's Common Customs Law states the consequence in a single sentence: "Goods taken out from free zones and duty-free shops into the local markets are subject to the customs tariff effective at that time."¹⁷

Read those last four words again. Not the rate when the goods entered the zone. The rate in force when they leave it. In a period when pharmaceutical tariffs are moving by proclamation, storing product in a zone does not lock a rate. It defers the decision into whatever regime exists later.

The UAE position is the clearest published example: goods enter the zone without customs duty and may be stored indefinitely, but "customs duty is only paid when goods are moved out of the free zone; that is, imported into the UAE", against a deposit equal to the full duty value which is refunded on re-export.¹⁸ Against a standard rate of 5 percent, that converts a permanent cost into a refundable deposit for goods that ultimately re-export, and defers rather than removes it for goods that land locally.

What to actually do

Four questions, none of which your regulatory function will answer.

Is your target market one of the eight? If not, someone has set a tariff rate on your HS heading and you should have the number before you price, not after.

Is your product zero-rated or exempt, and through which channel? Those are different economics, and the answer can change with a shift in how the product is delivered rather than any change in law.

Does your licence agreement make a royalty a condition of supply? If it does, that royalty is probably in your customs value, and the duty and import VAT consequences are compounding.

And what did you assume about tariffs? If the answer is zero because pharmaceuticals are always zero, that assumption is now a live exposure in the largest market in the world.

None of this is exotic. It is published, checkable, and mostly free to look up. It is simply owned by nobody, which is why it is where the surprises live.

Methodology and gaps

Every figure above is sourced to the WTO, the World Customs Organization, a national customs or tax authority, a legislative register or the US Federal Register. Where a schedule could not be retrieved, no rate is given.

Specifically not established, and therefore not asserted: Chapter 30 applied rates for Brazil, Argentina, Indonesia, Nigeria, Egypt, Turkey and Vietnam; the current 2026 Chinese rate, as distinct from the verified 2018 reduction; India's base rate as distinct from its exemption lists; the Gulf tariff line for medicines; VAT treatment of medicines in most non-EU markets; the product list in Annex I of Proclamation 11020 at subheading level; and whether any WTO notification has been made in respect of that proclamation. Australia appears among the 1994 signatories but not on the WTO's current participant list, and we found no primary document explaining the difference.

Position as at 12 August 2026. Tariff and tax positions change; verify before acting.